表紙
市場調查報告書
商品編碼
1040619

間品質性肺部疾病(ILD)市場:各疾病類型,各藥物類型,各流通管道,各地區:規模,佔有率,展望,機會分析(2021∼2028年)

Interstitial Lung Disease Market, by Disease Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球間品質性肺部疾病(ILD)市場上,由於來自法規機關的藥物核準的數增加,在預測期間內預計促進成長。藥物的銷售數增加,預期更加促進市場成長。

本報告提供全球間品質性肺部疾病市場相關調查分析,市場概要,市場動態、法規、趨勢分析,COVID-19影響分析,各疾病類型、藥物類型、流通管道、地區分析,競爭情形等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各疾病類型
    • 市場明細:各藥物類型
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 重要的開發
  • 市場趨勢
  • 科技形勢
  • 新設備/產品的銷售
  • PEST分析
  • 波特的五力分析

第4章 COVID-19影響分析

  • 需求的影響
  • 醫療保健的影響

第5章 全球間品質性肺部疾病:各疾病類型(2017∼2028年(100萬美元))

  • 簡介
  • 間質性肺病變
  • 特發性肺纖維化
  • 非特異性間質性肺病變
  • 過敏性肺炎
  • 化膿性組織性肺炎(COP)
  • 類肉瘤病
  • 急性間質性肺病變

第6章 全球間品質性肺部疾病:各藥物類型(2017∼2028年(100萬美元))

  • 簡介
  • 皮質類固醇
  • 抗纖維化藥物
  • Pirfenidone
  • Nintedanib

第7章 全球間品質性肺部疾病:各流通管道(2017∼2028年(100萬美元))

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球間品質性肺部疾病:各地區(2017∼2028年(100萬美元))

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • MSD(Merck)
    • Liminal Biosciences
    • Glenmark Pharma
    • J.B. Chemicals & Pharmaceuticals
    • Boehringer Ingelhim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Cipla
  • 分析師的見解

第10章 Section

目錄
Product Code: CMI4798

Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:

  • Shortness of breath at rest
  • Dry cough

The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study:

  • This report provides an in-depth analysis of global interstitial lung disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global interstitial lung disease market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.

Detailed Segmentation:

  • Global Interstitial Lung Disease Market, By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • Global Interstitial Lung Disease Market, By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • Global Interstitial Lung Disease Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interstitial Lung Disease Market, By Region:
    • North America
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Latin America
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Disease Type:
    • Interstitial Pneumonia
    • Idiopathic Pulmonary Fibrosis
    • Nonspecific Interstitial Pneumonitis
    • Hypersensitivity Pneumonitis
    • Cryptogenic Organizing Pneumonia (COP)
    • Sarcoidosis
    • Acute Interstitial Pneumonitis
  • By Drug Type:
    • Corticosteroids
    • Anti-fibrotic Medication
    • Pirfenidone
    • Nintedanib
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • MSD (Merck) *
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Liminal Biosciences
  • Glenmark Pharma
  • J.B. Chemicals & Pharmaceuticals
  • Boehringer Ingelhim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Cipla

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Development
  • Market Trends
  • Technology Landscape
  • New Device/Product Launches
  • PEST Analysis
  • Porter's Five Forces Analysis

4. COVID - 19 Impact Analysis

  • Impact on Demand
  • Impact on Healthcare

5. Global Interstitial Lung Disease, By Disease Type, 2017-2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Interstitial Pneumonia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Idiopathic Pulmonary Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nonspecific Interstitial Pneumonitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hypersensitivity Pneumonitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Cryptogenic Organizing Pneumonia (COP)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Sarcoidosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Acute Interstitial Pneumonitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Interstitial Lung Disease, By Drug Type, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-fibrotic Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Pirfenidone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nintedanib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Interstitial Lung Disease, By Distribution Channel, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Interstitial Lung Disease, By Region, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
    • MSD (Merck)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Liminal Biosciences
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Glenmark Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • J.B. Chemicals & Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Boehringer Ingelhim International GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Cipla
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact